Shire PLC (NASDAQ:SHPG)’s share price gapped up prior to trading on Thursday . The stock had previously closed at $166.86, but opened at $171.50. Shire shares last traded at $178.13, with a volume of 4168095 shares traded.
A number of equities analysts have issued reports on the company. BidaskClub cut Shire from a “buy” rating to a “hold” rating in a report on Friday, November 30th. ValuEngine raised Shire from a “sell” rating to a “hold” rating in a report on Thursday. Zacks Investment Research reaffirmed a “hold” rating on shares of Shire in a report on Thursday, November 15th. B. Riley reissued a “buy” rating on shares of Shire in a research note on Tuesday. Finally, Berenberg Bank cut Shire from a “buy” rating to a “hold” rating in a research note on Friday, September 7th. Nine investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $201.11.
The company has a market cap of $52.13 billion, a price-to-earnings ratio of 11.49, a PEG ratio of 1.54 and a beta of 1.01. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 0.36.
Shire (NASDAQ:SHPG) last released its earnings results on Thursday, November 1st. The biopharmaceutical company reported $3.64 EPS for the quarter, missing the consensus estimate of $3.65 by ($0.01). Shire had a return on equity of 12.70% and a net margin of 30.63%. The business had revenue of $3.87 billion for the quarter. During the same period in the prior year, the company earned $3.81 earnings per share. Shire’s revenue for the quarter was up 4.7% compared to the same quarter last year. On average, equities research analysts anticipate that Shire PLC will post 15.09 earnings per share for the current fiscal year.
A number of large investors have recently made changes to their positions in SHPG. Abrams Capital Management L.P. bought a new position in Shire in the third quarter worth approximately $407,338,000. Third Point LLC bought a new position in Shire in the third quarter worth approximately $290,032,000. PointState Capital LP boosted its holdings in Shire by 4,642.0% in the second quarter. PointState Capital LP now owns 711,296 shares of the biopharmaceutical company’s stock worth $120,067,000 after acquiring an additional 696,296 shares in the last quarter. OZ Management LP bought a new position in Shire in the third quarter worth approximately $71,720,000. Finally, Kepos Capital LP boosted its holdings in Shire by 400.0% in the third quarter. Kepos Capital LP now owns 425,000 shares of the biopharmaceutical company’s stock worth $77,040,000 after acquiring an additional 340,000 shares in the last quarter. Institutional investors and hedge funds own 20.49% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Shire (SHPG) Shares Gap Up to $171.50” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/12/07/shire-shpg-shares-gap-up-to-171-50.html.
About Shire (NASDAQ:SHPG)
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Featured Story: Capital Gains
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.